G1 Therapeutics Announces Initiation of Phase 1b/2 Clinical Trial of G1T38 in Combination with Tagrisso for EGFR-Mutant Non-Small Cell Lung Cancer
pharmaceutical investing Adaptimmune Reports Fourth Quarter / Full Year 2017 Financial Results and Business Update
pharmaceutical investing Corvus Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results
Heat Biologics Presents Immune Data on its HS-410 Phase 2 Bladder Cancer Trial at the Genitourinary Cancers Symposium
QIMC Defines Multiple New Hydrogen Hot Zones in Nova Scotia, Reports Stronger Preliminary DDH-26-05 Hydrogen Readings and Triples 2026 Nova Scotia Exploration Program Across a 43-km District-Scale Corridor
